menu
    • menu

    Company profile for Amphera

    NEW Drugs in Dev: 1
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Amphera is an advanced-clinical-stage biotechnology company developing dendritic cell therapies to treat cancer. Amphera’s management team has extensive experience of building successful life science companies and creating high-value shareholder exit opportunities. The Company has three ongoing clinical programmes with MesoPher – its personalised immuno-oncology cell therapy, comprised of autologous dendritic cells loaded ...
    Amphera is an advanced-clinical-stage biotechnology company developing dendritic cell therapies to treat cancer. Amphera’s management team has extensive experience of building successful life science companies and creating high-value shareholder exit opportunities. The Company has three ongoing clinical programmes with MesoPher – its personalised immuno-oncology cell therapy, comprised of autologous dendritic cells loaded with PheraLys, its proprietary allogeneic lysate of cancer cell lines. The lead programme is in a pivotal phase II/III study in pleural mesothelioma – a cancer of the lining of the lungs.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    AmpheraNetherlands1 Flag
    Country
    Country
    Netherlands
    Address
    Address
    Onderwijsboulevard 225 5223 DE 's-Hertogenbosch
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.amphera.nl/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/amphera/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Natural Product Expo West

    Natural Product Expo West

    Not Confirmed

    envelop Contact Supplier

    Natural Product Expo West

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Mitazalimab Shows Immune Activation In Metastatic Pancreatic
    Mitazalimab Shows Immune Activation In Metastatic Pancreatic

    13 Oct 2025

    // ACCESSWIRE

    https://www.accessnewswire.com/newsroom/en/biotechnology/reactive-2-phase-1-data-featuring-mitazalimab-demonstrate-immune-activation-in-metast-1086027

    ACCESSWIRE
    13 Oct 2025
    Share Share
    MesoPher Increases RFS Rate In Pancreatic Cancer; Orphan Status
    MesoPher Increases RFS Rate In Pancreatic Cancer; Orphan Status

    25 Sep 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240924023419/en

    BUSINESSWIRE
    25 Sep 2024
    Share Share
    Amphera Announces a Positive Opinion of EMA on the Granting of Orphan Medicinal Product Designation for MesoPher
    Amphera Announces a Positive Opinion of EMA on the Granting of Orphan Medicinal Product Designation for MesoPher

    06 Jun 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230604005030/en

    BUSINESSWIRE
    06 Jun 2023
    Share Share
    Amphera reports topline results from MesoPher cell therapy trials
    Amphera reports topline results from MesoPher cell therapy trials

    14 Dec 2022

    // CLINICALTRIALSARENA

    https://www.clinicaltrialsarena.com/news/amphera-mesopher-cell-therapy/

    CLINICALTRIALSARENA
    14 Dec 2022
    Share Share
    Amphera Announces Clinical Updates of MesoPher Cell Therapy
    Amphera Announces Clinical Updates of MesoPher Cell Therapy

    12 Dec 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20221212005204/en

    BUSINESSWIRE
    12 Dec 2022
    Share Share
    Last patient completed followup period in PII/III study of MesoPher cell therapy
    Last patient completed followup period in PII/III study of MesoPher cell therapy

    01 Aug 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20220801005324/en

    BUSINESSWIRE
    01 Aug 2022
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search